Spyre Therapeutics News

Spyre Therapeutics | 424B5: Prospectus

Nov 19 16:42 ET

Spyre Therapeutics | 424B5: Prospectus

Nov 18 17:15 ET

Spyre Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

Oct 25 16:33 ET

Spyre Therapeutics | EFFECT: Others

Oct 3 06:06 ET

Spyre Therapeutics | EFFECT: Others

Sep 19 06:05 ET

Spyre Therapeutics | 424B3: Prospectus

Aug 8 15:14 ET

Spyre Therapeutics | 424B3: Prospectus

May 15 16:17 ET

Spyre Therapeutics | EFFECT: Others

Apr 30 06:11 ET

Spyre Therapeutics | EFFECT: Others

Apr 2 06:04 ET

Spyre Therapeutics | EFFECT: Others

Apr 2 06:04 ET

Spyre Therapeutics | 424B3: Prospectus

Mar 18 16:14 ET

Spyre Therapeutics | 424B3: Prospectus

Feb 7 06:05 ET

Spyre Therapeutics | 424B3: Prospectus

Dec 8, 2023 16:06 ET

Spyre Therapeutics | 424B3: Prospectus

Nov 30, 2023 17:18 ET

Aeglea BioTherapeutics | EFFECT: Others

Nov 21, 2023 00:15 ET

Aeglea BioTherapeutics | 424B5: Prospectus

Mar 2, 2023 07:24 ET

Aeglea BioTherapeutics | 424B5: Prospectus

May 20, 2022 16:02 ET

Aeglea BioTherapeutics | 424B5: Prospectus

May 6, 2022 07:15 ET

Aeglea BioTherapeutics | FWP: Filing under Securities Act Rules 163/433 of free writing prospectuses

May 5, 2022 16:06 ET

Aeglea BioTherapeutics | 424B5: Prospectus

Feb 9, 2022 16:08 ET